Dr. Krunal Tamakuwala
MD, DM (Cardiology),
Internventional Cardiology,
KD, Hospital Ahmedabad

The PARAGON-HF trial analyzed the effects of Sacubitril/Valsartan on heart failure patients\ with preserved ejection fraction (HFpEF). The study found that patients on no diuretic and those on >40mg of loop diuretic had the lowest incidence of first events. The effects of Sacubitril/Valsartan on recurrent events did not significantly vary by baseline diuretic use. Safety outcomes of treatment were similar in all diuretic categories. Sacubitril/Valsartan reduced new loop diuretic initiations over the trial, with similar rates of diuretic and loop diuretic dose discontinuation between treatment groups in follow-up. Patients randomized to Valsartan/Sacubitril experienced a slight early reduction in diuretic initiation or dose escalation at 30 days after initiation.

Click Here to view the article:

National Library of Medicine